European Union market Zagreb · meetings by appointment info@eucri.com
Post-market surveillance

Undesirable effects and cosmetovigilance after product launch

How to receive, assess, document and report undesirable and serious undesirable effects associated with cosmetic products in the EU.

Safety obligations continue after launch. Complaints and undesirable effects may require a renewed product assessment, corrective action or reporting to a competent authority.

Complaint or undesirable effect?

A complaint may concern quality, packaging, odour or performance, whereas an undesirable effect is an adverse reaction for human health attributable to normal or reasonably foreseeable use.

One event may represent both a quality complaint and a safety signal. Initial triage should ensure that medically relevant information is not lost within general customer service.

Information to collect

Relevant details include the reporter, user, product, batch, use, timing, symptoms, course of the event and other possible causes. Only information needed for assessment should be collected, with appropriate privacy safeguards.

Photographs, medical documentation or a product sample may be useful but should be obtained through a controlled process. Each case needs a unique reference and communication record.

Practical checkpoint

Every conclusion should be linked to the exact formula, document and market-material version. This makes it possible to demonstrate which evidence supported the regulatory decision.

Assessing seriousness and causality

A serious undesirable effect meets defined severity criteria such as functional incapacity, hospitalisation, immediate vital risk or death. Such an event requires rapid action and reporting under the applicable requirements.

Causality assessment considers timing, reaction site, re-exposure, product properties, other products and medical conditions. The conclusion, including uncertainty, should be documented.

When a safety signal changes the CPSR

An individual case or trend may show that assumptions about use, target population, warnings or reaction frequency are no longer adequate. The safety assessor should receive the relevant information.

Actions may include additional monitoring, revised directions or warnings, reformulation, restricted distribution, withdrawal or recall. Decisions should be proportionate and traceable.

System ownership and trend review

The Responsible Person should define who receives cases, who performs medical or regulatory assessment, who communicates with authorities and how cover is maintained during absence.

Periodic trending by product, batch, market and event type can identify a signal that is not visible from one report. Findings feed risk management and quality systems.

Frequently asked questions

Must every complaint be reported to an authority?

Not every complaint is externally reportable, but every complaint should be triaged and documented under a procedure.

What is a serious undesirable effect?

It is an undesirable effect meeting seriousness criteria in the Regulation, such as hospitalisation or significant functional incapacity.

Must the CPSR be updated after a report?

The safety assessor should assess the new information; the extent of any update depends on the findings and risk.

Official sources and further reading

This article is for general information and does not replace an assessment of the specific product, formula and supply chain. Legislation and guidance may change after publication.

Next step

Apply the requirements to your product.

Send the product type, target markets and available documentation. We will reply by email.

Request a proposal ↗